Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 22 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Apnimed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (44): Smaller than most of the companies we track.
Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on APMD, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APMD appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 62% of US stocks
Cheaper than 16% of US stocks
Cheaper than 34% of US stocks
Cheaper than 40% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 14% of US stocks
Higher than 44% of US stocks
Higher than 39% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Apnimed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Apnimed made its Nasdaq debut, offering public investors their first pure-play opportunity in a pill-based treatment for obstructive sleep apnea (OSA).
Why it matters — The listing gives Apnimed watchers a direct public-market stake in the development of an oral alternative to CPAP machines for sleep apnea.
As at 22 Aug 2026, Apnimed, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (44 of 100).
No analyst covering Apnimed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APMD are extrapolating price history, which says nothing about the business.
Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on developing and commercializing novel oral therapies for sleep-related breathing diseases.
The most recent item we track (24/7 Wall Street, 14 Aug 2026): "Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks". Apnimed made its Nasdaq debut, offering public investors their first pure-play opportunity in a pill-based treatment for obstructive sleep apnea (OSA).
Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on developing and commercializing novel oral therapies for sleep-related breathing diseases. Its core specialization is obstructive sleep apnea, where it aims to address the underlying neuromuscular dysfunction that contributes to airway collapse during sleep. Apnimed’s lead product candidate, AD109, also known as Oxnimbi, is an investigational, fixed-dose oral combination therapy designed as a once-daily, at-bedtime pill to improve upper airway muscle activity and oxygenation in adults with mild to severe obstructive sleep apnea. The company is advancing a broader portfolio of oral therapeutic candidates for sleep-related breathing disorders, positioning itself within the healthcare and biotechnology sectors at the intersection of drug discovery, clinical development, and sleep medicine. Apnimed primarily serves physicians, sleep centers, and healthcare systems seeking pharmacologic alternatives to device-based treatments, with an emphasis on convenient, non-invasive options. Founded in 2017 and headquartered in Cambridge, Massachusetts, Apnimed operates today as a specialized player in neurobiology-driven therapies for sleep-related breathing conditions.
CEO Mr. Kevin Robert Lind · 65 employees · United States · https://apnimed.com